Nimbly adapts bioinformatics tools, visualization packages, and annotation resources to perform accurate research analysis– flexibility and competency in data…
From Medical College of Wisconsin - Fri, 20 May 2022 03:09:19 GMT - View all Milwaukee, WI jobs

Funding Opportunity PAR-22-186 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

Notice NOT-GM-22-037 from the NIH Guide for Grants and Contracts

Competitive Salary: F. Hoffmann-La Roche AG: Senior Software Engineer in TestImpact HealthcareRoche Sequencing is not only changing science, but we are changing lives. Our software teams are layi Ottawa (Region), Ontario (CA)

Competitive Salary: F. Hoffmann-La Roche AG: Impact HealthcareRoche Sequencing is not only changing science, but we are changing lives! Our team is pushing the boundary of technology with next-ge United States (US)

Competitive Salary: F. Hoffmann-La Roche AG: Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, is focused on developing a disruptive Next-Generation Sequencing (NGS) platform United States (US)

Negotiable: Oxford Nanopore Technologies: We are looking for an individual with expertise in bioinformatics and an in-depth knowledge of the range and limitations of existing bioinformatics t New York, New York

Funding Opportunity RFA-NS-22-036 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. This program is distinct from the NINDS P01 in that it will support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams are encouraged to consider transformative objectives with defined 5-year outcomes.

Notice NOT-OD-22-126 from the NIH Guide for Grants and Contracts

Notice NOT-HD-22-023 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-22-180 from the NIH Guide for Grants and Contracts. The goal of this initiative is to support research to improve the mental health of mobile populations, such as refugees, internally displaced persons, and migrants through improved diagnosis, prevention, and treatment approaches. Of specific interest is research that addresses the mental health care of priority populations such as children and youth, people with serious mental illness, sexual and gender minorities, people with disabilities, and separated families.

Notice NOT-CA-22-087 from the NIH Guide for Grants and Contracts

Adapts bioinformatics tools, visualization packages, and annotation resources for research projects to independently and accurately perform research analysis,…
From Medical College of Wisconsin - Tue, 17 May 2022 09:11:46 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-NS-22-056 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications from experienced investigators seeking to conduct exploratory clinical trials designed to test new treatments for patients with Lewy Body Dementia (LBD). Applicants may propose to conduct either Phase I or Phase II clinical trials depending on the developmental stage of the potential therapeutic, but all trials must include patients with LBD. Proposed therapies may include novel medications or devices, or existing treatments that are potentially beneficial but not currently approved for use in patients with LBD. Treatments intended to prevent or delay disease progression in LBD patients, as well as therapies to alleviate existing motor or non-motor clinical symptoms, are of interest.

Funding Opportunity RFA-DA-23-008 from the NIH Guide for Grants and Contracts. Stimulant use has been increasing among opioid users since 2016, based on overdose data and this makes control of the opioid epidemic more difficult, as it occurs in addition to the continuing influx of fentanyl and related compounds. Stimulant/opioid users present unfamiliar clinical issues to providers and experienced providers often find polysubstance users less motivated to address stimulant use. Stimulant use also has continued to account for a substantial fraction of HIV cases among gay men and other MSM. Much of this use is problematic/episodic (meth, cocaine, ketamine) and does not rise to the level of SUD or represents mild SUD despite problematic practices (syringe sharing, unprotected sex, etc.). We have limited tools for stimulant treatment and even fewer tools for addressing non-SUD or mild SUD stimulant use. New initiatives should incorporate new treatments as they become available. Particular attention is needed re: stimulant use in the context of polysubstance use that includes opioids including identification of motivations and contexts for more effectively implementing intervention.

Funding Opportunity RFA-NS-22-066 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for research projects to test promising cerebrovascular interventions in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion, tMCAo). The PIs of the awarded interventions will become part of the network and will collaborate with the SPAN Coordinating Center (RFA-NS-22-004), testing laboratories (RFA-NS-22-003), and other intervention contributors (RFA-NS-22-066, RFA-NS-22-067) to facilitate the parallel testing of multiple cerebroprotective interventions in experimental models of ischemic stroke. Applicants must propose a promising cerebroprotective intervention, supported by rigorous and extensive preliminary data, to be tested in SPAN. If successful, this network will accelerate the identification of the most promising cerebroprotective therapies for future pivotal clinical trials and span the gap between small businesses, preclinical testing laboratories, and a pipeline to clinical testing, in a cost-and time-effective fashion.

Notice NOT-HL-22-023 from the NIH Guide for Grants and Contracts

Notice NOT-AI-22-051 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-132 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-184 from the NIH Guide for Grants and Contracts. Reissue PAR-19-220.